Use of selective serotonin-reuptake inhibitors in the first trimester and risk of cardiovascular-related malformations: a meta-analysis of cohort studies

<u>Tie-Ning Zhang¹, Shan-Yan Gao², Zi-Qi Shen³, Da Li³, Cai-Xia Liu³, Hai-Chen Lv⁴, Yuan Zhang⁵, Ting-Ting Gong³, Xin Xu², Chao Ji², Qi-Jun <u>Wu², *</u></u>

Supplementary Table S1. Characteristics of cohort studies in the meta-analysis

First author (ref), year, location	No. of cohort/cases	Study period	Outcomes	Risk estimates (95% CI)	Adjusted factors
Furu et al ³⁰ ,	2,303,647	1996-2010		Odds Ratio	Maternal age, year of birth, birth order, smoking,
2015, Europe	27,309		Any cardiac defect	1.15 (1.05-1.26)	maternal diabetes, country, and use of other prescribed drugs.
	17,879		ASD and VSD	1.17 (1.05-1.31)	
	1,095		Atrioventricular septal defect	1.22 (0.77-1.91)	
	2,261		Conotruncal and major arch Anomalies	0.95 (0.67-1.35)	
	2,641		Left ventricular outflow tract Obstruction	1.09 (0.80-1.49)	
	2,778		Right ventricular outflow tract Obstruction	1.48 (1.15-1.89)	
	657		Situs anomalies and looping defect	1.00 (0.52-1.90)	
Berard	18,493	1998-2010		Risk Ratio	Maternal age, welfare status, diabetes, .
et al ³¹ , 2015, North	405		Cardiac malformations	1.10 (0.82-1.48)	hypertension,asthma,and other medication use
America	322		ASD/VSD	1.30 (0.99-1.70)	

First author	No. of	Study	Outcomes	Risk estimates	Adjusted factors
(ref), year,	cohort/cases	period		(95% CI)	
location					
Ban et al ³² ,	349,127	1990-2009		Odds Ratio	Maternal age at the end of pregnancy, year of
2014, Europe	2,512		Specific heart anomalies	1.14 (0.89-1.45)	childbirth,townsend deprivation quintile, maternal smoking history,BMI before pregnancy, and
	N/A		Septal defect	0.89(0.63-1.27)	maternal diabetes, hypertension, asthma, and epilepsy in the year before conception or during
	N/A		ASD	1.68 (0.98-2.91)	pregnancy.
	N/A		VSD	0.63(0.38-1.03)	
	N/A		LVOTD	1.05 (0.20-11.24)	
	N/A		RVOTD	2.22 (0.98-5.03)	
Huybrechts et al ³³ , 2014,	949,504	2000-2007		Odds Ratio	N/A
North	6,819		Cardiac	1.25 (1.13-1.38)	
America			malformations		
	3,413		VSD	1.20 (1.04-1.39)	
	1,106		Right ventricular outflow tract	1.12 (0.87-1.45)	
	3,458		obstruction Other cardiac defect	1.34 (1.17-1.54)	

First author (ref), year,	No. of cohort/cases	Study period	Outcomes	Risk estimates (95% CI)	Adjusted factors
location	72.200	1005 2000		0.11 D .:	
Knudsen	72,280	1995-2008		Odds Ratio	Maternal age, year of conception, use of
et al 34 , 2014,	546		CHD	1.64 (0.89-3.00)	antiepileptics and/or insulin during first trimester.
Europe	129		Severe CHD	4.03 (1.75-9.26)	
	97		ASD	2.82 (0.88-9.04)	
	333		VSD	0.94 (0.35-2.53)	
	54		Pulmonary valve stenosis	3.47 (0.83-14.5)	
Vasilakis- Scaramozza	9,893	1991-2002		Relative Risk	Prepregnancy BMI, maternal age, cigarette smoking status, history of DM, insulin use, exposure to a
et al ³⁵ , 2013, Europe	35		Cardiovascular anomalies	0.80 (0.40-1.90)	teratogen during the first trimester, history of infertility, and premature delivery.
Margulis et al ³⁶ , 2013, Europe	149,464	1996-2010		Odds Ratio	Year of delivery, maternal age at delivery, prepregnancy marital status, index of multiple deprivation at the practice level, family history of congenital malformations, prepregnancy body mass, prepregnancy diabetes, cigarette
	721		Cardiac malformations	1.09 (0.66-1.79)	smoking, alcohol intake, diagnosis of depression in baseline year, diagnosis of other mental
	N/A		Septal defects	1.12 (0.60-2.09)	conditions in baseline year or contact with or referral to a psychiatrist, number of health care encounters in baseline year and number of nonantidepressant drugs prescribed in baseline year.

First author	No. of	Study	Outcomes	Risk estimates	Adjusted factors
(ref), year,	cohort/cases	period		(95% CI)	
location					
Nordeng et al ³⁸ , 2012,	63,395	1999-2009		Odds Ratio	Maternal depression, maternal age at delivery, parity, and use of psychotropic drugs during
Europe	547		Cardiovascular anomalies	1.51 (0.67-3.43)	pregnancy.
	N/A		ASD/VSD	1.57 (0.64-3.87)	
Jimenez-	848,786	1997-2009		Odds Ratio	Mother's age, parity, income, education, smoking,
Solem et al ³⁹ , 2012,	7,832		Congenital malformation of heart	2.01 (1.60-2.53)	And year of conception.
Europe					
	2,524		ASD	2.60 (1.84-3.68)	
	N/A		Atrioventricular sepetal defect	1.25 (0.31-5.02)	
	2,824		VSD	1.62 (1.05-2.50)	
	4,875		Septal defect	2.04 (1.53-2.72)	
Colvin et al	123,405	2002-2005		Odds Ratio	N/A
2011, other	691		Cardiovascular	1.60 (1.10-2.31)	
regions			anomalies		
	97		Ostium secundum type ASD	2.73 (1.26-5.89)	
	218		VSD	0.99 (0.44-2.23)	

First author (ref), year,	No. of cohort/cases	Study period	Outcomes	Risk estimates (95% CI)	Adjusted factors
location					
	382		Bulbus cordis anomalies and anomalies of cardiac septal closure	1.23 (0.71-2.15)	
	250		Other congenital anomoly of heart	1.77 (0.99-3.16)	
Malm et al ³⁷ ,	635,583	1996-2006		Odds Ratio	Age at the end of pregnancy, parity, year of
2011, Europe	8,253		All major cardiovascular anomalis	1.09 (0.90-1.32)	pregnancy ending, smoking during pregnancy, purchase of other reimbursed psychiatric drugs during the first trimester, and maternal
	1,297		ASD	1.04 (0.64-1.69)	prepregnancy diabetes.
	5,550		VSD	1.20 (0.96-1.50)	
	437		Conotruncal heart defect	0.46 (0.14-1.46)	
	476		Left ventricular outflow tract defects	0.93 (0.40-2.13)	
	423		Right ventricular outflow tract defects	1.74 (0.85-3.57)	
	240		Transposition of great arteries	0.60 (0.15-2.52)	

First author	No. of	Study	Outcomes	Risk estimates	Adjusted factors
(ref), year,	cohort/cases	period		(95% CI)	
location					
Kornum	216,042	1991-2007		Odds Ratio	Maternal smoking status, maternal age, birth order,
et al ⁴⁰ , 2010,	1,429		Cardiac	1.70 (1.10-2.50)	and birth year.
Europe			malformations		
	N/A		Septal heart defect	1.40 (0.80-2.30)	
Merlob	67,871	2000-2007		Relative Risk	N/A
et al ²⁰ ,2009,	1,091		Congenital heart	2.17 (1.07-4.39)	
Other regions			malformation		
Pedersen	493,113	1996-2003		Odds Ratio	Age, calendar year, income, marriage status,
et al ¹⁹ , 2009,	4,004		Major cardiac	1.44 (0.86-2.40)	tobacco smoking.
Europe			malformations		
	2,327		Septal heart defects	1.99 (1.13-3.53)	
Oberlander	11,957	1998-2001		Odds Ratio	N/A
et al ²² , 2008,	529		Cardiovascular	1.36 (0.84-2.21)	
North			congenital defects		
America	81		ASD	3.28 (1.42-7.53)	
	225		VSD	1.12 (0.50-2.52)	

First author (ref), year, location	No. of cohort/cases	Study period	Outcomes	Risk estimates (95% CI)	Adjusted factors
Davis et al ⁴¹ ,	87,407	1996-2000		Relative Risk	Health system, maternal age, and birth season.
2007, North	682		Bulbus cordis	0.93 (0.50-1.73)	
America			anomalies and anomalies of cardiac septal closure		
	506		Other congenital anomolies of heart	0.88 (0.42-1.86)	
Kallen	880,431	1995-2004		Odds Ratio	Year of birth, maternal age, parity, smoking, and≥3
et al ⁴² , 2007,	11,445		Any cardiac defect	0.97 (0.77-1.21)	Previous miscarriages.
Europe	7,213		VSD and/or ASD	1.10 (0.84-1.44)	
	1,218		Unspecified cardiac defect	1.04 (0.42-2.15)	
Kulin et al ⁴³ ,	534			Relative Risk	N/A
1998, North	6		Cardiac	0.53 (0.10-2.86)	
America			malformations		

Abbreviations: ASD, atrial septal defect; BMI, body mass index; CHD, congenital heart defect; DM, diabetes mellitus; LVOTD, left ventricular outflow tract defect; N/A, not available; RVOTD, right ventricular outflow tract defect; VSD, ventricular septal defect.

Supplementary Table S2. Methodological quality of cohort studies included in the meta-analysis^a

First author (reference), publication year	Representativeness of the exposed cohort	Selection of the unexposed cohort	Ascertainment of exposure	Outcome of interest not present at start of study	Control for important factor or additional factor b	Assessment of outcome	Follow-up long enough for outcomes to occur ^c	Adequacy of follow-up of cohorts
Furu et al ³⁰ , 2015	*	*	*	*	**	*	*	*
Berard et al ³¹ , 2015	*	*	*	*	*	*	*	*
Ban et al ³² , 2014	*	*	*	*	**	*	_	-
Huybrechts et al ³³ , 2014	*	*	*	*	-	*	*	*
Knudsen et al ³⁴ , 2014	*	*	*	*	*	*	*	*
Vasilakis- Scaramozza et al ³⁵ , 2013	*	*	*	*	**	*	*	*
Margulis et al ³⁶ , 2013	*	*	*	*	**	*	*	*
Nordeng et al ³⁸ , 2012	*	*	*	*	*	*	-	-
Jimenez- Sole et al ³⁹ , 2012	*	*	*	*	**	*	*	*
Colvin et al ²¹ , 2011	*	*	*	*	_	*	*	*
Malm et al ³⁷ , 2011	*	*	*	*	**	*	-	-
Kornum et al 40, 2010	*	*	*	*	**	*	*	*
Merlob et al ²⁰ , 2009	*	*	*	*	-	*	*	*
Pedersen et al ¹⁹ , 2009	*	*	*	*	**	*	*	*
Oberlander et al ²² , 2008	*	*	*	*	-	*	-	-
Davis et al ⁴¹ , 2007	*	*	*	*	*	*	*	*
Kallen et al ⁴² , 2007	*	*	*	*	**	*	-	-
Kulin et al ⁴³ , 1998	*	*	*	*		*	-	

^a A study could be awarded a maximum of one star for each item except for the item Control for important factor or additional factor. The definition/explanation of each column of the Newcastle-Ottawa Scale is available from (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.).

^b A maximum of 2 stars could be awarded for this item. Studies that controlled for age received one star, whereas studies that controlled for other important confounders such as smoking and/or alcohol using received an additional star.

^c A cohort study with a follow-up time >9 months was assigned one star.

^d A cohort study with a follow-up rate >75% was assigned one star.